Wesana Health is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana Health is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Investor Note: In addition to the 20,633,772 Subordinate Voting Shares that are listed and trading, there are 14,324,200 shares reserved specifically for issuance pursuant to the conversion rights attached to the Super Voting Shares and Multiple Voting Shares that are issued and outstanding but not listed.  The total number of equity shares assuming all are converted into the listed class would be 34,957,972.  

WPD Pharmaceuticals is a biotechnology research and development company. The Company operates in the pharmaceuticals industry with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. The Issuer is developing drugs which were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.